Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, View ORCID ProfileAndi Krumbholz
doi: https://doi.org/10.1101/2021.07.09.21260251
Ruben Rose
1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
Franziska Neumann
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Olaf Grobe
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Thomas Lorentz
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Helmut Fickenscher
1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
Andi Krumbholz
1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Article usage
Posted July 13, 2021.
Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, Andi Krumbholz
medRxiv 2021.07.09.21260251; doi: https://doi.org/10.1101/2021.07.09.21260251
Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, Andi Krumbholz
medRxiv 2021.07.09.21260251; doi: https://doi.org/10.1101/2021.07.09.21260251
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (676)
- Anesthesia (182)
- Cardiovascular Medicine (2676)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12304)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4149)
- Geriatric Medicine (389)
- Health Economics (684)
- Health Informatics (2688)
- Health Policy (1009)
- Hematology (365)
- HIV/AIDS (859)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3931)
- Nursing (212)
- Nutrition (584)
- Oncology (2068)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (252)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1128)
- Primary Care Research (461)
- Public and Global Health (6572)
- Radiology and Imaging (1418)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)